financetom
Business
financetom
/
Business
/
Roper Technologies Announces $1.65 Billion CentralReach Acquisition, Targets 20%+ Growth
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Roper Technologies Announces $1.65 Billion CentralReach Acquisition, Targets 20%+ Growth
Mar 24, 2025 9:01 AM

Roper Technologies, Inc. ( ROP ) shares are trading higher on Monday after the company disclosed a deal to acquire CentralReach from Insight Partners for a net purchase price of around $1.65 billion.

The acquisition price factors in a $200 million tax benefit.

CentralReach offers cloud-based software designed to streamline the workflow and administration of Applied Behavior Analysis (ABA) therapy.

The platform also features AI-powered modules to enhance efficiency and care outcomes.

Roper plans to integrate CentralReach into its Application Software segment, with anticipated sustainable 20%+ organic revenue and EBITDA growth.

Notably, CentralReach is projected to generate around $175 million in revenue and $75 million in EBITDA for the 12 months ending June 30, 2026.

The acquisition, expected to close by April/May 2025, is subject to regulatory approval and customary conditions and will be financed through Roper’s revolving credit facility.

“This acquisition is another example of Roper identifying a business that provides greater value creation for our shareholders,” said Neil Hunn, Roper’s president and CEO.

”CentralReach meets each of our long-standing acquisition criteria, while also having a structurally faster organic growth profile and the ability to expand margins under Roper’s long-term ownership.”

As of FY24, the company had cash and equivalents of $188.2 million and net inventories worth $120.8 million.

Investors can gain exposure to the stock via Invesco Water Resources ETF ( PHO ) and Invesco Global Water ETF ( PIO ) .

Price Action: ROP shares are up 0.42% at $574.58 at the last check Monday.

Read Next:

Consumer Tech News (Mar 17-Mar 21): Google To Acquire Wiz, US Bans DeepSeek, Nvidia Does Big Revealation At GTC 2025 Event & More

Photo: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Frontdoor Q1 EPS, Revenue Surpass Expectations, Maintains 2024 Outlook; Shares Rise
Frontdoor Q1 EPS, Revenue Surpass Expectations, Maintains 2024 Outlook; Shares Rise
May 2, 2024
12:25 PM EDT, 05/02/2024 (MT Newswires) -- Frontdoor ( FTDR ) shares advanced Thursday, recently climbing almost 6%, following its better-than-expected Q1 results. Earlier, the company reported Q1 adjusted net income of $0.44 per diluted share, compared with $0.29 a year earlier. Analysts polled by Capital IQ expected $0.20. Revenue for the quarter ended March 31 was $378 million, up...
Belden Shares Rise After Q1 EPS, Revenue Exceed Consensus; Enters Deal to Acquire Precision Optical
Belden Shares Rise After Q1 EPS, Revenue Exceed Consensus; Enters Deal to Acquire Precision Optical
May 2, 2024
12:25 PM EDT, 05/02/2024 (MT Newswires) -- Belden (BDC) shares were up 7.7% in recent Thursday trading after the company reported Q1 adjusted income and revenue ahead of consensus. The company reported Q1 adjusted income of $1.24 per diluted share, down from $1.68 a year earlier. Four analysts polled by Capital IQ expected $1.06. Revenue for the quarter ended March...
--Toronto-Dominion Bank Fined $6.7 Million by Canadian Regulator Over Anti-Money Laundering Non-Compliance
--Toronto-Dominion Bank Fined $6.7 Million by Canadian Regulator Over Anti-Money Laundering Non-Compliance
May 2, 2024
12:23 PM EDT, 05/02/2024 (MT Newswires) -- Price: 58.86, Change: +0.16, Percent Change: +0.28 ...
Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises
Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises
May 2, 2024
12:18 PM EDT, 05/02/2024 (MT Newswires) -- Kymera Therapeutics ( KYMR ) reported a Q1 net loss Thursday of $0.69 per diluted share, narrower than a loss of $0.70 a year earlier. Analysts polled by Capital IQ expected a loss of $0.73. Collaboration revenue for the quarter ended March 31 was $10.3 million, up from $9.5 million a year earlier....
Copyright 2023-2026 - www.financetom.com All Rights Reserved